Oncology Research Pipeline

For Boehringer Ingelheim, Cancer Care is personal - today and for generations

We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, and treatments for a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad directive, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.

Explore our pipeline

Highlights

Find out more

Clinical trial: Beamion LUNG-2

Phase III trial of zongertinib in the treatment of NSCLC with documented HER2 mutation

Find out more

Clinical trial: Dareon-5

Phase II trial of a DLL3/CD3 T-cell engager (BI 764532) in the treatment of SCLC and other NECs